CTOs on the Move


 
  • Number of Employees:
  • Annual Revenue:

  • ,

Executives

Name Title Contact Details

Similar Companies

AXIS Automation

AXIS Automation is an industry leading manufacturing company backed by over 35 years of experience and global reach. We provide a wide range of innovative automated decorating and finishing solutions for the baking and snack food industry. Our drive is our customers. Weve worked with over 400 clients, including Fortune 100 and 500 companies around the world, to perfect their product and streamline their process for greater output and less waste. We are committed to providing reliable, accurate, and efficient systems that deliver better quality product at higher production rates and lower cost. PRECISION With our machinery, consistency and quality always come first. When your product comes out just as expected, every time, you waste fewer ingredients and save more money. Our engineers work with the unique requirements of your product to achieve accurate and precise decorating and finishing solutions. FLEXIBILITY When we design our equipment, we keep in mind that giving you more possibilities allows you more control over your product. Thats why we incorporate flexibility of use into all of our machines so that you can manage which ingredients you use, application rates and production volume. INNOVATION Working with AXIS means finding the solution to your unique production requirements and achieving the consistency and accuracy your product demands. Each machine is designed with both functionality and footprint in mind to streamline your process at an economical and eco-friendly price, ensuring you the highest return on investment. The success of our customers is the result of our dedication to the precision, flexibility and innovation of our equipment that is Built to Last and Designed to Deliver.™

Harmony Bank

Our approach consists of four primary factors: 1. Provide a personalized experience with every customer interaction. 2. Offer products with inherent value that address unique customer needs. 3. Locally owned and operated. 4. Loans deployed to assist local businesses and residents. Member FDIC. Equal Housing Lender.

SLAM

For 27 years and counting, SLAM has been the most authentic brand in basketball storytelling. What started as a magazine in 1994 has now grown into a global lifestyle brand and multimedia property with 20-plus social channels, a burgeoning merchandise division and multiple franchise events annually. With over 16 million engaged followers across the globe, SLAM and its channels reach fans of the NBA, WNBA, college and high school, and the worlds of fashion, sneakers, gaming and more in a unique and trusted voice. The cover of SLAM remains the Holy Grail for basketball players; if you want to play in the NBA or WNBA, you want to be on the cover of SLAM.

IMUNON

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.